The value of serum FGL1 and LncSChLAP1 in the assessment of immune therapeutic effect and prognosis of ad-vanced non-small cell lung cancer

Xia Ning; Zhou Zejun; Fang Shencun; Wang Zunqiao; Pan Yanqing

doi:10.3969/j.issn.1671-6450.2024.03.017

Abstract：Objective To investigate the efficacy and prognostic evaluation value of fibrin like factor 1(FGL1)and long chain non-coding RNA SChLAP1(LncSChLAP1)in immunotherapy for patients with advanced non-small cell lung cancer(NSCLC).Method Ninety-eight patients with advanced NSCLC diagnosed and treated in the Department of Respira-tory Medicine of Nanjing Chest Hospital from April 2019 to December 2022 were selected as the NSCLC group,all of them were treated with immune checkpoint inhibitors,and were divided into effective subgroups(74 cases)and ineffective sub-groups(24 cases)according to the therapeutic efficacy,and 50 cases of those who had a healthy physical examination in hospitals during the same period of time were selected as the healthy control group.The NDT was detected by enzyme-linked immunosorbent assay.Enzyme-linked immunosorbent assay(ELISA)was used to detect serum FGL1 levels in NSCLC patients,and real-time fluorescence quantitative PCR was used to detect serum LncSChLAP1 levels;multifactorial logistic re-gression analysis was used to analyze the factors affecting the efficacy of chemotherapy in patients with advanced NSCLC;subjects'work characteristic curves were used to analyze the predictive value of serum FGL1 and LncSChLAP1 on the effi-cacy of immunotherapy in patients with advanced NSCLC The predictive value of serum FGL1 and LncSChLAP1 on the sur-vival and prognosis of advanced NSCLC patients was analyzed by Kaplan-Meier curve.Results The serum FGL1 and Lnc-SChLAP1 levels were higher in the NSCLC group than in the healthy control group(t/P=57.365/<0.001,28.443/<0.001).The proportion of TNM stage IV,serum FGL1,and LncSChLAP1 levels were higher in the ineffective subgroup than in the effec-tive subgroup(χ2/P=15.375/<0.001,t/P=35.077/<0.001,35.127/<0.001).Serum FGL1 andLncSChLAP1 were independent risk factors affecting the efficacy of immunotherapy in patients with advanced NSCLC[OR(95%CI)=1.327(1.104-1.596),1.415(1.094-1.829)];serum FGL1,LncSChLAP1 and the AUC of the two combined were 0.856,0.792,and 0.905,respectively,and the combination of the two was superior to the predicted efficacy of each one alone(Z/P=4.258/0.007,25.119/<0.001).The 1-year overall survival rates were 22.92%(11/48)and 60.00%(30/50)in the FGL1 high and low expression groups,re-spectively,and 27.66%(13/47)and 54.90%(28/51)in the LncSChLAP1 high and low expression groups,respectively,and the 1-year overall survival rates in the FGL1 high expression group and LncSChLAP1 high expression group and Lnc-SChLAP1 high-expression group were lower than the 1-year cumulative survival rates of advanced NSCLC patients in the FGL1 low-expression group and the LncSChLAP1 low-expression group,respectively(Log-Rankχ2/P= 14.180/<0.001,17.553/<0.001).Conclusion Elevated serum FGL1 and LncSChLAP1 in patients with advanced NSCLC are new serum markers for evaluating the efficacy of immunotherapy and survival prognosis in patients with advanced NSCLC.